Waleed H. Hassanein Sells 4,000 Shares of TransMedics Group, Inc. (NASDAQ:TMDX) Stock

TransMedics Group, Inc. (NASDAQ:TMDX) CEO Waleed H. Hassanein sold 4,000 shares of the firm’s stock in a transaction dated Wednesday, April 17th. The stock was sold at an average price of $95.12, for a total transaction of $380,480.00. Following the completion of the sale, the chief executive officer now owns 74,087 shares of the company’s stock, valued at $7,047,155.44. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

TransMedics Group Price Performance

Shares of NASDAQ TMDX opened at $84.16 on Friday. TransMedics Group, Inc. has a twelve month low of $36.42 and a twelve month high of $99.63. The firm has a market cap of $2.75 billion, a P/E ratio of -109.30 and a beta of 1.99. The company has a 50 day moving average of $82.88 and a 200 day moving average of $73.19. The company has a quick ratio of 8.49, a current ratio of 9.30 and a debt-to-equity ratio of 3.69.

TransMedics Group (NASDAQ:TMDX) last announced its quarterly earnings data on Monday, February 26th. The company reported $0.12 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.10) by $0.22. TransMedics Group had a negative net margin of 10.36% and a negative return on equity of 2.35%. The company had revenue of $81.20 million during the quarter, compared to analyst estimates of $68.49 million. During the same period in the previous year, the business earned ($0.21) EPS. The firm’s revenue for the quarter was up 158.6% on a year-over-year basis. As a group, research analysts expect that TransMedics Group, Inc. will post -0.14 EPS for the current fiscal year.

Hedge Funds Weigh In On TransMedics Group

A number of hedge funds have recently added to or reduced their stakes in the company. Harbour Capital Advisors LLC raised its holdings in TransMedics Group by 1.7% in the 4th quarter. Harbour Capital Advisors LLC now owns 8,371 shares of the company’s stock worth $627,000 after acquiring an additional 140 shares during the last quarter. First Horizon Advisors Inc. raised its holdings in TransMedics Group by 45.1% in the 1st quarter. First Horizon Advisors Inc. now owns 544 shares of the company’s stock worth $41,000 after acquiring an additional 169 shares during the last quarter. Belpointe Asset Management LLC grew its position in TransMedics Group by 51.6% in the 1st quarter. Belpointe Asset Management LLC now owns 558 shares of the company’s stock worth $42,000 after purchasing an additional 190 shares during the period. RiverPark Advisors LLC grew its position in TransMedics Group by 19.5% in the 4th quarter. RiverPark Advisors LLC now owns 1,319 shares of the company’s stock worth $104,000 after purchasing an additional 215 shares during the period. Finally, Price T Rowe Associates Inc. MD grew its position in TransMedics Group by 2.0% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 14,512 shares of the company’s stock worth $896,000 after purchasing an additional 288 shares during the period. 99.67% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

TMDX has been the subject of several research analyst reports. Oppenheimer raised their price objective on shares of TransMedics Group from $92.00 to $105.00 and gave the stock an “outperform” rating in a report on Tuesday, February 27th. Piper Sandler initiated coverage on shares of TransMedics Group in a report on Thursday, March 28th. They set an “overweight” rating and a $95.00 target price for the company. Morgan Stanley lifted their target price on shares of TransMedics Group from $75.00 to $95.00 and gave the company an “equal weight” rating in a report on Wednesday, February 28th. Finally, JPMorgan Chase & Co. lifted their target price on shares of TransMedics Group from $87.00 to $105.00 and gave the company an “overweight” rating in a report on Tuesday, February 27th. One investment analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. According to MarketBeat.com, TransMedics Group currently has an average rating of “Moderate Buy” and a consensus price target of $102.00.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.